Xeris Biopharma Holdings XERS
NASDAQ XERS
$16.52 +0.69 (+4.36%)
At close: Nov 11, 2026 · 4:00 PM EST

Xeris Biopharma Holdings (XERS) Long-Term Debt Repayments (2022)

Updated

Xeris Biopharma Holdings' Long-Term Debt Repayments was $43.5 million in FY2022.

Analysis

Xeris Biopharma Holdings (XERS) Long-Term Debt Repayments (2022) Analysis & Trends

  • Per Business Quant data, Long-Term Debt Repayments in earlier years was $25.09 million in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 1.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -4.91 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 3.05 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 19.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Xeris Biopharma Holdings 2.89 Bn 2.41 Bn 94.80 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 43.50 Mn
API Access

Xeris Biopharma Holdings Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=XERS&period=max&api_key=YOUR_API_KEY